Global Chronic Lymphocytic Leukemia market 2016-2020

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL
Technavio’s analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffman-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Gilead Sciences
  • Novartis
  • Johnson & Johnson
Other prominent vendors
  • Altor BioScience
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Biogen
  • BioLineRx
  • Boston Biomedical
  • Celgene
  • Emergent BioSolutions
  • Genzyme
  • iDD biotech
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MedImmune
  • Merck Sharp & Dohme
  • Molecular Templates Inc.
  • MorphoSys
  • Ono Pharmaceutical
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology
Market driver
  • Special regulatory designations
  • For a full, detailed list, view our report
Market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Market trend
  • Rise in development of combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020

Technavio recognizes the following companies as the key players in the global chronic lymphocytic leukemia therapeutics market: F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, and Novartis.

Other Prominent Vendors in the market are: Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

Commenting on the report, an analyst from Technavio’s team said: “A trend that is expected to boost market growth is a rise in the development of combination therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. The approved combinations are chlorambucil in combination with prednisone, and a combination of cyclophosphamide with vincristine and prednisone. However, a growing trend of developing combination therapies to treat CLL has been observed. For instance, TG Therapeutics develops TG-1101 in combination with ibrutinib to treat CLL and MCL. Similarly, the company also develops TG-1101 in combination with TGR-1202 to treat CLL and NHL.”

According to the report, a key growth driver is the special regulatory designations offered to certain drugs. Diseases that affect a small percentage of the population, such as CLL, are treated by a few marketed drugs. A small number of patients implies that there is a small market for these0 drugs, so it may not be profitable for companies to develop these drugs as recovering the R&D expenses would be difficult. To compensate for this limitation and encourage the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs.

Further, the report states that one challenge that could restrict market growth is the high cost of therapy. Since R&D costs to develop new drugs is very high, manufacturers pass on costs to buyers, which is a big burden.

Companies Mentioned

Amazon India, Flipkart.com, Snapdeal, Jabong, Yepme, 20Dresses.com, 99labels, Alibaba, American Swan, Fabindia, FashionandYou, Fetise, HomeShop18, KOOVS, Limeroad, Naaptol, Shopclues.com, Shoppers Stop, Shopping.indiatimes, Shopping.rediff, StalkBuyLove.com, Styletag, Stylista, Yebhi.com.F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, Novartis, Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, ZIOPHARM Oncology.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Timeline of development of leukemia drugs
  • Disease overview
    • Understanding the disease
      • Table Snapshot of CLL
    • Types of CLL
      • Table Types of CLL
    • Symptoms
    • Diagnosis
      • Table Main diagnostic procedures to determine presence of CLL
      • Table Other diagnostic procedures to determine presence of CLL
    • Staging
      • Table Rai stages of CLL
      • Table Binet stages of CLL
    • Management
      • Table Management of CLL
    • Key buying criteria
      • Table Key buying criteria for CLL drugs
  • Pipeline analysis
    • Table Pipeline portfolio: Global CLL therapeutics market
    • Acalabrutinib
    • TG-1101 + ibrutinib
    • TGR-1202
    • Venetoclax + obinutuzumab
    • Venetoclax + rituximab
    • REVLIMID
    • Duvelisib
      • Table Percentage share of drug candidates by stage of development 2015
  • Market landscape
    • Global CLL therapeutics market
      • Table Global CLL therapeutics market 2015-2020 ($ billions)
    • Total addressable market for global CLL therapeutics
      • Table Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by ROA
    • Table Segmentation of global CLL therapeutics market by ROA 2015
    • Oral
    • Parenteral
  • Market segmentation by type of molecule
    • Table Segmentation of global CLL therapeutics market by type of molecule 2015
    • Small molecules
    • Biologics
  • Geographical segmentation
    • Global CLL therapeutics market by geographical segmentation 2015-2020
      • Table Segmentation of global CLL therapeutics market based on geography 2015
      • Table Segmentation of global CLL therapeutics market based on geography 2020
      • Table Global CLL therapeutics market by geography 2015-2020 ($ millions)
      • Table Global CLL therapeutics market by geography 2015-2020
    • CLL therapeutics market in Americas
      • Table CLL therapeutics market in Americas 2015-2020 ($ billions)
    • CLL therapeutics market in EMEA
      • Table CLL therapeutics market in EMEA 2015-2020 ($ billions)
    • CLL therapeutics market in APAC
      • Table CLL therapeutics market in APAC 2015-2020 ($ millions)
      • Table Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Special regulatory designations
    • Recent drug approvals
    • Application for expanded indication approvals
    • Increase in patient pool
      • Table Population aged 60 years and over: World, developed, and developing regions (millions)
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High cost of therapy
      • Table Cost of therapy for CLL
    • Availability of chemotherapy and off-label drugs
    • Adverse effects of drugs
    • Stringent regulatory guidelines
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Joint ventures and partnerships
    • Patient assistance programs
    • Rise in development of combination therapies
    • Growing public awareness
  • Vendor landscape
    • Competitive scenario
      • Table SWOT: MabThera
      • Table SWOT: Imbruvica
      • Table SWOT: Treanda
      • Table SWOT of Zydelig
    • Market share analysis 2015
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
      • Table MabThera/Rituxan geographic segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: Key takeaways
    • AbbVie
      • Table AbbVie: Key takeaways
    • Teva Pharmaceuticals
      • Table Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
      • Table Teva Pharmaceuticals: Key takeaways
    • Johnson & Johnson
      • Table Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
      • Table Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
      • Table Johnson & Johnson: Geographic segmentation of Imbruvica 2015
      • Table Johnson & Johnson: Key takeaways
    • Gilead Sciences
      • Table Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
      • Table Gilead Sciences: Key takeaways
    • Novartis
      • Table Novartis: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook